Biofrontera Inc. 8-K

What Happened
Biofrontera Inc. filed a Form 8-K on February 9, 2026 (Item 7.01, Regulation FD Disclosure) to announce the results of its Phase 3 clinical study of Ameluz® photodynamic therapy (PDT) for actinic keratoses on the extremities, neck, and trunk. The company furnished a press release with the full announcement as Exhibit 99.1 to the filing (press release dated February 9, 2026), which is incorporated by reference into the 8-K.

Key Details

• Filing date: February 9, 2026 (Form 8-K, Item 7.01).
• Subject: Results from Biofrontera’s Phase 3 study of Ameluz® PDT for actinic keratoses located on extremities, neck, and trunk.
• Disclosure method: Press release provided as Exhibit 99.1 to the 8-K (also noted in Item 9.01).
• The 8-K is a Regulation FD disclosure, making the information public and furnished to the SEC.

Why It Matters
A Phase 3 study is a late-stage clinical milestone for a therapeutic product. By publicly disclosing these study results via an 8-K and press release, Biofrontera has provided material clinical information that investors can use to assess the company’s clinical and regulatory progress for Ameluz®. Investors should review the Exhibit 99.1 press release (filed with the 8-K) for the detailed data, conclusions, and any stated next steps from management.